-
公开(公告)号：US10578621B2
公开(公告)日：2020-03-03
申请号：US14814165
申请日：2015-07-30
Applicant: Samsung Electronics Co., Ltd.
Inventor： Ji Min Lee , Bo Gyou Kim , Kyung Ah Kim , Seung Ja Oh
IPC: G01N33/574 , C07K16/30
Abstract: A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.
-
2.发明申请公开(公告)号：US20160144027A1
公开(公告)日：2016-05-26
申请号：US14949041
申请日：2015-11-23
Inventor： Seon Hui Shim , Ji Min Lee , Soo Yeon Jung , Woo Sun Kwon , Kyung Ah Kim , Jeong Min Kim , Sun Young Rha , Won Suk Lee
IPC: A61K39/395 , G01N33/574 , A61K31/4985
CPC classification number: A61K39/39558 , A61K31/00 , A61K31/4985 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/52 , C07K2317/622 , C07K2317/92 , C07K2319/00 , G01N33/57492 , G01N33/74 , G01N2333/65 , G01N2800/52 , A61K2300/00
Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.
Abstract translation: 一种预防和/或治疗癌症的方法，所述方法包括将c-Met（以下称为“c-Met抑制剂”）和IGF-1R抑制剂的双重抑制剂共同给予有需要的受试者，以及使用 IGF-1R作为c-Met抑制剂抗性的标志物。
-
公开(公告)号：US20160053025A1
公开(公告)日：2016-02-25
申请号：US14835376
申请日：2015-08-25
Applicant: Samsung Electronics Co., Ltd.
Inventor： Seungja Oh , Kyung Ah Kim , Bo Gyou Kim , Seung Hyun Lee , Ji Min Lee
IPC: C07K16/40 , A61K39/395 , A61K38/18 , C07K16/22
CPC classification number: A61K38/18 , A61K38/1891 , A61K2039/507 , A61K2039/545 , C07K16/22 , C07K16/2863 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2317/73 , C07K2317/92 , A61K2300/00
Abstract: An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.
Abstract translation: 一种抗c-Met /抗Ang2双特异性抗体，包括（a）抗c-Met抗体或其抗原结合片段和（b）抗Ang2抗体或其抗原结合片段，药物组合物包括 抗c-Met /抗Ang2双特异性抗体，以及使用抗c-Met /抗Ang2双特异性抗体的方法。
-
4.发明申请公开(公告)号：US20160033518A1
公开(公告)日：2016-02-04
申请号：US14814165
申请日：2015-07-30
Applicant: Samsung Electronics Co., Ltd.
Inventor： Ji Min Lee , Bo Gyou Kim , Kyung Ah Kim , Seung Ja Oh
IPC: G01N33/574 , C07K16/30 , C07K16/40
CPC classification number: G01N33/57496 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , G01N2333/91205
Abstract: A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.
Abstract translation: 用于预测靶向c-Met和EGFR的双靶向药物的功效的生物标志物PNCK和预测靶向c-Met和EGFR的双靶向药物的作用的方法，选择受试者应用 靶向c-Met和EGFR的双重靶向剂，或监测靶向c-Met和EGFR的双重靶向剂的作用，包括测量PNCK和/或PNCK编码基因的水平。
-
5.发明申请公开(公告)号：US20150010575A1
公开(公告)日：2015-01-08
申请号：US14323642
申请日：2014-07-03
Applicant: SAMSUNG ELECTRONICS CO., LTD. , GEORGETOWN UNIVERSITY
Inventor： Bo Gyou KIM , Shangzi Wang , Ji Min Lee , Kyung Ah Kim , Louis M. Weiner
CPC classification number: C12Q1/6886 , A61K38/08 , A61K38/10 , A61K38/1774 , A61K38/1808 , A61K39/39558 , A61K45/06 , C07K16/2836 , C12Q2600/106 , C12Q2600/158 , G01N33/5011 , G01N33/5023 , G01N2800/52 , A61K2300/00
Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.
Abstract translation: 用于与抗c-Met抗体组合治疗的靶物质，用于预防和/或治疗癌症的组合用药物组合物，包括抗c-Met抗体和针对所述靶物质的抑制剂作为活性成分的方法 用于预防和/或治疗癌症，包括共同施用抗c-Met抗体和针对靶物质的抑制剂，以及使用目标物质筛选用于预防和/或治疗癌症的药物的方法。
-
Patent Agency Ranking
公开(公告)号：US20140212414A1
公开(公告)日：2014-07-31
申请号：US14167711
申请日：2014-01-29
Applicant: Samsung Electronics Co., Ltd.
Inventor： Young Mi OH , Kyung Ah Kim
IPC: A61K39/395 , A61K31/496 , C07K16/32
CPC classification number: A61K31/496 , A61K31/122 , A61K31/497 , A61K39/39558 , A61K45/06 , C07K16/2863 , A61K2300/00
Abstract: A method of preventing and/or treating a cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof.
Abstract translation: 一种预防和/或治疗癌症的方法，包括将p53激活剂和c-Met抑制剂共同给予有需要的患者。
-
7.发明授权公开(公告)号：US10064939B2
公开(公告)日：2018-09-04
申请号：US14949041
申请日：2015-11-23
Inventor： Seon Hui Shim , Ji Min Lee , Soo Yeon Jung , Woo Sun Kwon , Kyung Ah Kim , Jeong Min Kim , Sun Young Rha , Won Suk Lee
IPC: A61K39/395 , A61K31/00 , C07K16/28 , A61K31/4985 , G01N33/574 , G01N33/74 , A61K39/00
Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.
-
8.发明授权Method of treating cancer using anti-c-Met antibody and FGFR inhibitor combination therapy 有权使用抗c-Met抗体和FGFR抑制剂联合治疗治疗癌症的方法公开(公告)号：US09192666B2
公开(公告)日：2015-11-24
申请号：US14242684
申请日：2014-04-01
Applicant: Samsung Electronics Co., Ltd.
Inventor： Bo Gyou Kim , Ji Min Lee , Kyung Ah Kim , Yun Ju Jeong
IPC: A61K39/395 , C07K16/30 , C07K16/28 , A61K31/506 , A61K31/519 , A61K39/00
CPC classification number: A61K39/39558 , A61K31/506 , A61K31/519 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/52 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/00 , A61K2300/00
Abstract: Provided is a method for prevention or treatment of a cancer, comprising co-administering (a) an FGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope comprising 5 or more contiguous amino acids within the SEMA domain of c-Met protein.
Abstract translation: 本发明提供一种预防或治疗癌症的方法，其包括将（a）FGFR抑制剂和（b）抗c-Met抗体或其抗原结合片段共同给予有需要的受试者，其中， c-Met抗体或其抗原结合片段特异性结合到c-Met蛋白的SEMA结构域内包含5个或更多个连续氨基酸的表位。
-
公开(公告)号：US20150140014A1
公开(公告)日：2015-05-21
申请号：US14081886
申请日：2013-11-15
Applicant: Samsung Electronics Co., Ltd.
Inventor： Seung Hyun LEE , Geun Woong Kim , Kyung Ah Kim , Hye Won Park , Ho Yeong Song , Young Mi Oh , Saet Byoul Lee , Ji Min Lee , Kwang Ho Cheong , Yun Ju Jeong , Mi Young Cho , Jae Hyun Choi , Yun Jeong Song , Yoon Aa Choi
IPC: C07K14/71 , A61K31/437 , A61K31/44 , A61K39/395 , A61K31/517
CPC classification number: A61K31/437 , A61K31/44 , A61K31/517 , A61K39/3955 , A61K39/39558 , C07K16/2863 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/30 , C12N5/163 , A61K2300/00
Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.
Abstract translation: 一种预防或治疗癌症的方法，包括共同给予（a）抗c-Met抗体或其抗原结合片段，和（b）拉帕替尼，替罗非尼，伏马拉净或其组合中的至少一种， （a）抗c-Met抗体或其抗原结合片段，和（b）拉帕替尼，替罗非尼，伏马拉净或其组合中的至少一种提供给药物组合物 。
-
公开(公告)号：US20150071932A1
公开(公告)日：2015-03-12
申请号：US14481509
申请日：2014-09-09
Applicant: Samsung Electronics Co., Ltd.
Inventor： Ji Min Lee , Kyung Ah Kim
IPC: A61K39/395 , A61K31/7088
CPC classification number: A61K31/7088 , A61K31/713 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K2317/24 , A61K2300/00
Abstract: A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a c-Myc Inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a c-Myc inhibitor, and a kit comprising a pharmaceutically effective amount of a c-Met inhibitor as an active ingredient, and a second pharmaceutical composition comprising a pharmaceutically effective amount of a c-Myc inhibitor as an active ingredient, packaged together.
Abstract translation: 一种预防和/或治疗癌症的方法，包括向有需要的受试者共同施用c-Met抑制剂和c-Myc抑制剂，包含c-Met抑制剂和c-Myc抑制剂的药物组合物和 试剂盒包含药学上有效量的c-Met抑制剂作为活性成分，以及包含药学有效量的作为活性成分的c-Myc抑制剂的第二药物组合物，包装在一起。
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.024 seconds)
